Around 144 cannabinoids have been identified in cannabis plant, among them tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prominent ones. The market for cannabis and cannabinoids has experienced significant growth in recent years, driven by a combination of changing regulatory landscapes, increasing consumer demand and growing recognition of the potential health and wellness benefits associated with these compounds. As a cutting-edge laboratory, ABF is at the forefront of this scientific journey and has already developed methods for the bioanalysis of cannabis and cannabinoids. These methods are characterized by its level of sensitivity, automation, throughput and can be used for pharmacokinetic studies, exposure assessment and risk evaluation.